Fierce Pharma

JULY 14, 2023

The potentially curative promise of gene therapies often carries a steep price tag. | The potentially curative promise of gene therapies often carries a steep price tag. But for a pair of personalized medicine prospects in sickle cell disease (SCD), the cost could be worth it, at least as far as ICER is concerned.

82

82

Pharmaceutical Technology

NOVEMBER 9, 2022

On November 2, the Institute for Clinical and Economic Review (ICER) released its updated evidence aimed at measuring the clinical effectiveness and cost of the two haemophilia gene therapies. million price tag. The greater durability has also served as a factor in ICER giving EtranaDez a higher fair price estimate, says Rind.

FDA 111

FDA 111

pharmaphorum

OCTOBER 3, 2022

Chief medical officer at the independent drug pricing watchdog, Institute for Clinical and Economic Review (ICER), David Rind said Relyvrio should have been priced closer to the cost of production until there is clear proof about its efficacy. The post Amylyx ALS drug draws criticism over $158,000 price tag appeared first on.

Insurance 52

Insurance FDA 52

pharmaphorum

APRIL 14, 2022

US cost-effectiveness watchdog ICER has handed bluebird bio some good news ahead of its FDA advisory committee meeting for rare blood disorder gene therapy beti-cel in June, by endorsing its proposed $2.1 million price tag. The post ICER says bluebird bio’s $2.1m gene therapy is cost-effective appeared first on.

FDA 62

FDA 62

STAT

AUGUST 2, 2023

Besides the $26,500 annual price tag, treatment could cost U.S. taxpayers $82,500 per patient per year, on average, for genetic tests, frequent brain scans, safety monitoring, and other care, according to the Institute for Clinical and Economic Review, or ICER. About 1 million Alzheimer’s patients in the U.S.

Insurance Coverage 69

Insurance Coverage Insurance 69

Pharmaceutical Technology

APRIL 13, 2023

Two gene therapies up for approval this year for sickle cell disease could be cost effective in some cases at a $2 million price point, based on a draft evidence report published by the Institute for Clinical and Economic Review (ICER). Still, comparing the two therapies remains difficult, with ICER rating the evidence as insufficient.

FDA 59

FDA 59

pharmaphorum

JUNE 8, 2021

That was the damning conclusion of the influential Institute for Clinical and Economic Review (ICER) in the US to yesterday’s approval of Aduhelm (aducanumab), the first new treatment for Alzheimer’s since 2003, which it says has “no evidentiary basis.” — Dr. Patrizia Cavazzoni (@FDACDERDirector) June 7, 2021.

FDA 98

FDA Labelling 98